The recognition of the importance of IL-1β in the pathogenesis of different disorders already resulted in the development of diverse therapeutic strategies inhibiting the IL-1 system mainly for the treatment of diverse autoimmune diseases (2, 8). This evidence concerns the gene IL1B and autoimmune disease.